MI
NBIX icon

Motiv8 Investments’s Neurocrine Biosciences NBIX Stock Holding History

Motiv8 Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6K Buy
+39
New +$5.65K ﹤0.01% 531

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Motiv8 Investments's NBIX Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Neurocrine Biosciences (NBIX) in Q4 2025: 39 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #531 among its holdings.

733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Motiv8 Investments held 39 shares of Neurocrine Biosciences worth $6K as of Q4 2025.
  • Neurocrine Biosciences was a new Motiv8 Investments position in Q4 2025.
  • Neurocrine Biosciences made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #531 holding.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.